Search the Newsreel

Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock. By their very nature, these stocks carry above-average risk and volatility. …

United States Antimony expands across Alaska, Montana and Ontario to boost domestic antimony supply

United States Antimony Corporation (NYSE: UAMY) is expanding its mining and exploration work across Alaska, Montana, and Ontario to increase domestic antimony supply for military and industrial customers. The company anticipates 2026 will be the first year its own mined ore contributes to customer …

HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up

Harmony Biosciences Holdings, Inc. HRMY reported second-quarter 2026 earnings of $1.28 per share, up from 68 cents in the year-ago quarter. The figure surpassed the Zacks Consensus Estimate of 97 cents. Quarterly revenues rose 30% year over year to $261.28 million and surpassed the …

Best UK Dividend Stocks to Watch: MONY Group (LSE:MONY) Leads Income Focus

Harmony Biosciences 2Q 2026: Revenue $261.28M, EPS $1.28— 10-Q Summary

Harmony Biosciences Holdings, Inc. reported strong second-quarter 2026 results, with revenue reaching $261.28 million and diluted EPS at $1.28, significantly up from the prior year. This growth was driven by increased product volume and a price adjustment in January 2026. The company also highlighted …

Sei Investments Co. Grows Position in Harmony Gold Mining Company Limited $HMY

Sei Investments Co. significantly increased its stake in Harmony Gold Mining Company Limited (NYSE:HMY) by 22% in the first quarter, now holding over 900,000 shares valued at approximately $13.9 million. Other institutional investors like Goldman Sachs, AQR Capital Management, and Lazard Asset Management also …

Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $70 at Oppenheimer

Oppenheimer analyst Andreas Argyrides has lowered the price target for Harmony Biosciences Holdings Inc. (HRMY) to $70. This information was updated on August 4, 2026, at 2:30 PM EDT. The full details of this analyst action are available only to premium subscribers of StreetInsider.com.

Oppenheimer lowers Harmony Biosciences stock price target on model updates

Oppenheimer has lowered its price target for Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) to $70 from $85, while maintaining an Outperform rating. This adjustment follows the company's strong second-quarter 2026 results, which saw Wakix net sales exceed estimates, and the reiteration of full-year 2026 guidance. …

MONY Group Cancels Nearly 200,000 Shares in Two-Day Buyback Blitz

Harmony Biosciences Holdings, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:HRMY)

Harmony Biosciences Holdings, Inc. released its Q2 2026 earnings, reporting an EPS of $1.50, which beat estimates by $0.35. The company's revenue reached $261.28 million, surpassing expectations by $8.01 million and showing a 30.32% year-over-year increase. This presentation accompanies their earnings call for the …

Harmony Biosciences Holdings Surges 11.0% Amid Sector-Wide Rally

Harmony Biosciences Holdings (HRMY) surged 11.0% to $39.50, driven by a sector-wide rally in biotechnology stocks, with peers like AMLX and NUVB also seeing gains. The company's stock experienced elevated trading volume, adding to its market capitalization of $2.3 billion. Positive analyst sentiment, including …

Harmony Biosciences (NASDAQ:HRMY) Stock Price Up 11.4% Following Strong Earnings

Harmony Biosciences Shares Rise After Q2 Earnings, Product Revenue Increase

Harmony Biosciences (NASDAQ: HRMY) lifts Q2 profit as WAKIX sales grow

Harmony Biosciences (HRMY) reported a significant increase in Q2 2026 profitability, with net product revenue rising to $261.28 million and net income reaching $75.43 million, driven by strong WAKIX sales. The company's pipeline includes Pitolisant GR with a PDUFA date of April 1, 2027, …

Harmony Biosciences Holdings, Inc. (HRMY) Beats Q2 Earnings and Revenue Estimates

Harmony Biosciences Holdings, Inc. (HRMY) reported Q2 earnings of $1.28 per share, significantly beating the Zacks Consensus Estimate of $0.97, and revenues of $261.28 million, surpassing estimates by 3.46%. Despite underperforming the market year-to-date, the company holds a Zacks Rank #1 (Strong Buy) due …

(HRMY) Harmony Biosciences Expects 2026 Wakix Net Revenue Range $1.0B to $1.04B

Harmony Biosciences Holdings, Inc. (HRMY) anticipates its 2026 net revenue from Wakix to be in the range of $1.0 billion to $1.04 billion. This announcement follows recent financial updates, including Q2 EPS of $1.28 and Q2 revenue of $261.3 million, both exceeding FactSet estimates. …

Earnings Flash (HRMY) Harmony Biosciences Holdings, Inc. Reports Q2 Revenue $261.3M, vs. FactSet Est of $250.8M

Harmony Biosciences Holdings, Inc. reported Q2 revenue of $261.3 million, surpassing FactSet's estimate of $250.8 million. The company, focused on therapies for rare neurological diseases, also announced its Q2 2026 earnings call and confirmed earnings results for the quarter and six months ended June …

Harmony Biosciences Holdings, Inc Q2 Profit Climbs

(RTTNews) - Harmony Biosciences Holdings, Inc (HRMY) released earnings for its second quarter that Increased, from last year The company's earnings totaled $75.43 million, or $1.28 per share. This compares with $39.78 million, or $0.68 per share, last year. The company's revenue for the …

Harmony Biosciences Announces Record Q2 2026 Revenue and

Harmony Biosciences reported record Q2 2026 revenue of $261.3 million for WAKIX, a 30% year-over-year increase, and reiterated its full-year guidance of $1.0 billion to $1.04 billion. The company also shared positive Phase 1 clinical data for its orexin-2 agonist BP-205, reinforcing its potential …

Harmony Biosciences (NASDAQ:HRMY) Announces Earnings Results, Beats Estimates By $0.32 EPS

Harmony Biosciences (HRMY) Stock Jumps On Profit Surge As Margin Pressure Lingers

A Look at Harmony Gold Mining Co Ltd (HMY) After 4.6% Gain -- GF Value $17.13 vs Price $16.47

Harmony Gold Mining Co Ltd (HMY) shares recently gained 4.6% and are currently trading at $16.47, which is 3.9% below its GF Value™ of $17.13, indicating it is undervalued. The company holds a strong GF Score™ of 88/100 due to robust fundamentals, particularly in …

Earnings To Watch: Harmony Biosciences Holdings Inc (HRMY) Q2 2026 -- GF Value Sees 57% Upside

Amundi Sells 127,982 Shares of Harmony Gold Mining Company Limited $HMY

Matrimony.com schedules investor call for Aug 11 to discuss Q1FY27 results

HGMCF SEC Filings - HARMONY GOLD MINING CO LTD 10-K, 10-Q, 8-K Forms

This page provides a comprehensive overview of HARMONY GOLD MINING CO LTD (HGMCF) SEC filings, including 10-K, 10-Q, and 8-K forms, enhanced with AI-generated summaries, sentiment, and impact scores. Recent filings detail Harmony Gold's 2025 Form 20-F availability, a fatal incident at the Mponeng …

Harmony Biosciences (HRMY) Stock Seems Undervalued As Earnings Hold Up

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Harmony Biosciences Holdings has delivered a 30.8% total return over the past 5 years, yet its current valuation checks on Simply Wall St …

Harmony Biosciences Holdings (HRMY) Following A Fresh Bullish Narrative, Is The Valuation Case Compelling

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Event driven interest around Harmony Biosciences Holdings stock Fresh attention is turning to Harmony Biosciences Holdings (HRMY) after research firm Zacks assigned the …

Income Investors Should Know That Matrimony.com Limited (NSE:MATRIMONY) Goes Ex-Dividend Soon

Harmony Biosciences (HRMY) Stock Looks Below Fair Value On Earnings

HRMY Maintained by Mizuho -- Price Target Raised to $51.00

Mizuho has maintained an "Outperform" rating for Harmony Biosciences Holdings (HRMY) and increased its price target to $51.00, reflecting optimism for the biotechnology company. HRMY is currently valued at $34.76, indicating a 26.5% undervaluation according to GuruFocus's GF Value™ of $47.30, and holds a …

Mizuho Lifts Price Target on Harmony Biosciences Holdings to $51 From $50, Keeps Outperform Rating

Mizuho has increased its price target for Harmony Biosciences Holdings (HRMY) to $51 from $50, while reiterating an Outperform rating. This adjustment suggests a continued positive outlook on the company's stock performance.

United States Antimony Corp (UAMY) Financial Health: Profitability & Balance Sheet Analysis

United States Antimony Corp (UAMY) has a weak financial status with a current financial score of 5.35, ranking 114 out of 126 in the Metals & Mining industry. The company's operating efficiency is low, with its latest quarterly revenue decreasing by 3.08% year-over-year and …

United States Antimony Corp (UAMY) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for United States Antimony Corp (UAMY), noting its current valuation score of 8.17, which ranks it 50th in the Metals & Mining industry. The company's P/E ratio is reported as -42.35, with relevant data for P/B, P/S, and …

HMY|Harmony Gold Mining Company Ltd|Price:16.160|Chg%:+0.630

Harmony Gold Mining Company Ltd (HMY) is a mining company with operations in South Africa, Papua New Guinea, and Australia, focusing on gold, uranium, and copper. The company's fundamentals are considered healthy with significant growth potential, high profit growth, and a strong dividend, though …

Is It Too Late to Buy Harmony Gold Mining Co Ltd (HMY) After 4.0% Rally? GF Value Says Undervalued

Harmony Gold Mining Co Ltd (HMY) experienced a 4.0% rally, with its shares currently trading at $16.15. According to GuruFocus' GF Value™, the stock is estimated to be 5.7% undervalued at $17.12, and its GF Score™ of 88/100 suggests strong overall performance, particularly in …